# Turn Therapeutics Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Turn Therapeutics Inc.). ## Overview Turn Therapeutics Inc. is a U.S.-based pharmaceutical and medical device development company built around a proprietary platform for formulating active ingredients in stable oil-based carriers. Its pipeline includes FDA-cleared medical devices, a device under De Novo review, and drug candidates in clinical and pre-clinical development for dermatology and other therapeutic areas. ## Products & services • FDA-cleared medical devices for dermatology and wound care • FleX medical device under De Novo clearance testing • Drug candidate for moderate-severe eczema and onychomycosis • Thermostable intranasal pharmaceutical candidate • PermaFusion formulation platform for drug delivery • Out-licensing and collaboration opportunities - **Medical devices** (35%) — FDA-cleared and in-development devices used for dermatology and related applications. - **Drug candidates** (25%) — Pharmaceutical programs in clinical and pre-clinical development, including dermatology and intranasal assets. - **Platform technology** (20%) — PermaFusion formulation technology used to stabilize polar APIs in oil-based carriers. - **Licensing and collaboration** (20%) — Out-licensing, development partnerships, and strategic arrangements for product commercialization. - FDA-cleared medical devices for dermatology and wound care - FleX medical device under De Novo clearance testing - Drug candidate for moderate-severe eczema and onychomycosis - Thermostable intranasal pharmaceutical candidate - PermaFusion formulation platform for drug delivery - Out-licensing and collaboration opportunities ## Customers Turn Therapeutics primarily serves pharmaceutical and medical device partners, regulators, and ultimately patients and clinicians in dermatology and related therapeutic areas. Its commercial model depends on licensing, manufacturing, and distribution partners that can take approved products to market in the U.S. and internationally. The end users for its products include patients with eczema, onychomycosis, and other conditions addressed by its device and drug candidates. - **Licensing and commercialization partners** (primary) — Companies that license Turn's products or platform and handle manufacturing, sales, and distribution. - **Healthcare providers** (secondary) — Dermatology and other clinicians who prescribe or use the company's cleared or approved products. - **Patients** (primary) — Individuals with eczema, onychomycosis, and other conditions targeted by the pipeline. - **Medical device manufacturers** (secondary) — Third parties that may produce or distribute licensed device products. - Pharmaceutical partners that license or co-develop product candidates - Medical device distributors and manufacturers for commercialization - Clinicians treating eczema, onychomycosis, and related conditions - Patients who use the cleared devices or future approved therapies - Regulatory stakeholders that determine product approval pathways ## Geography Turn Therapeutics is headquartered in the United States and develops products intended for U.S. and international markets. Its disclosures emphasize commercialization through third-party partners in the U.S. and abroad, so geography matters mainly through regulatory approvals, partner execution, and market access rather than owned manufacturing footprints. - Headquartered in the United States - Primary regulatory pathway is through the FDA - Products are intended for U.S. and international commercialization - Partner-led distribution may expand reach beyond the U.S. - No country revenue breakdown was disclosed in the excerpts ## Strategy The company is focused on advancing its device and drug pipeline through clinical testing, regulatory submissions, and product validation. A central strategic priority is to secure manufacturing, distribution, and licensing partners that can commercialize approved products without Turn building a large direct sales infrastructure. - **Regulatory advancement** (short-term) — Approval is the key gate to product sales and broader commercialization. - **Clinical development** (short-term) — Clinical data supports approval, labeling, and partner interest. - **Partner-led commercialization** (medium-term) — Third-party manufacturing and distribution can scale products faster than an internal buildout. - **Platform expansion** (long-term) — A reusable formulation platform can support multiple products and indications. - Advance FDA pathways for device and drug candidates - Complete clinical work supporting IND and later approvals - Use licensing and partnerships to commercialize products - Expand the pipeline across dermatology and vaccine-related programs - Leverage PermaFusion as a platform across multiple assets ## Risks Turn Therapeutics faces high regulatory and clinical development risk because its business depends on FDA clearances, IND acceptance, and successful trial outcomes. It also depends on external financing and partner execution, which can dilute shareholders or delay commercialization if capital or collaboration terms are unfavorable. - **Regulatory approval risk** [critical] — Products cannot be commercialized until FDA pathways are successfully completed. - **Clinical development failure or delay** [high] — Trial outcomes determine whether the company can advance to later-stage development and approval. - **Financing and dilution risk** [high] — The company expects to fund operations through equity, debt, and other capital sources. - **Partner execution risk** [medium] — Commercial success depends on third parties handling manufacturing, distribution, and sales. - **Competition and class-wide product risk** [medium] — Competing therapies or device issues can affect adoption and regulatory expectations. - FDA clearance and IND approval are uncertain and time-consuming - Clinical trials may fail, delay, or require additional studies - Commercialization depends on third-party partners and licensees - Additional financing may be dilutive or unavailable - Going-concern risk reflects dependence on future capital ## Accounting Revenue recognition is highly judgmental because the company has deferred revenue tied to a license agreement for FleX until FDA outcomes become more predictable. Investors should also watch capitalization of patent-related legal costs, stock-based compensation, and the valuation of intangible assets, since these items can materially affect reported assets and expenses. - **Deferred revenue from license agreement** — Can shift revenue recognition across periods - **Revenue recognition under ASC 606** — Affects timing and amount of reported revenue - **Capitalized patent legal costs** — Influences asset base and amortization expense - **Stock-based compensation** — Affects operating loss and equity dilution - **Going-concern assessment** — Signals financing dependence and survival risk - Deferred revenue tied to the FleX license agreement - ASC 606 judgment on when performance obligations are satisfied - Capitalized patent and trademark legal costs in intangibles - Stock-based compensation affects operating expense and equity - Lease accounting affects right-of-use assets and liabilities --- *Last updated: 2026-04-29T05:04:44.608937+00:00*